Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

Empagliflozin has kidney protective effects and reduces heart failure outcomes across baseline kidney function among patients with AMI.

Rezpeg's promising Phase 2b data makes Nektar Therapeutics a strong contender in the AD market. Click here to read an ...

Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Apollo HealthCo clocked a revenue of ₹9,093 crore in FY25, growing 16% year-on-year. The platform delivered three successive ...

Shares in biopharmaceutical company Viking Therapeutics (NASDAQ: VKTX) were up by 6.3% at 12:30 a.m. ET today. The move ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

The UK's health regulator is investigating Ozempic and Mounjaro after linking the drugs to hundreds of severe illnesses and ...

The label update for Amyvid adds guidance for assessing amyloid plaque levels and may help inform diagnostic and treatment ...

The UK is studying cases of pancreatitis in people taking drugs based on GLP-1 receptor agonists for weight loss or type 2 ...